Cancer Research Donn Young  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hofer, M. D.
Right arrow Articles by Rubin, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hofer, M. D.
Right arrow Articles by Rubin, M. A.
[Cancer Research 64, 825-829, February 1, 2004]
© 2004 American Association for Cancer Research


Advances in Brief

The Role of Metastasis-Associated Protein 1 in Prostate Cancer Progression

Matthias D. Hofer1,2, Rainer Kuefer3, Sooryanarayana Varambally4, Haojie Li5, Jing Ma5, Geoffrey I. Shapiro2,6, Juergen E. Gschwend3, Richard E. Hautmann3, Martin G. Sanda7, Klaudia Giehl8, Andre Menke9, Arul M. Chinnaiyan4,7 and Mark A. Rubin1,2

1 Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts; 2 Harvard Medical School, Boston, Massachusetts; 3 Department of Urology, University Hospital of Ulm, Ulm, Germany; 4 Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan; 5 Channing Laboratory, Department of Medicine, Harvard Medical School, Boston, Massachusetts; 6 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts; 7 Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan; 8 Department of Pharmacology and Toxicology, University of Ulm, Ulm, Germany; and 9 Department of Internal Medicine I, University Hospital of Ulm, Ulm, Germany

Distinguishing aggressive prostate cancer from indolent disease represents an important clinical challenge, as current therapy requires over treating men with prostate cancer to prevent the progression of a few cases. Expression of the metastasis-associated protein 1 (MTA1) has previously been found to be associated with progression to the metastatic state in various cancers. Analyzing DNA microarray data, we found MTA1 to be selectively overexpressed in metastatic prostate cancer compared with clinically localized prostate cancer and benign prostate tissue. These results were validated by demonstrating overexpression of MTA1 in metastatic prostate cancer by immunoblot analysis. MTA1 protein expression was evaluated by immunohistochemistry in a broad spectrum of prostate tumors with tissue microarrays containing 1940 tissue cores from 300 cases. Metastatic prostate cancer demonstrated significantly higher mean MTA1 protein expression intensity (score = 3.4/4) and percentage of tissue cores staining positive for MTA1 (83%) compared with clinically localized prostate cancer (score = 2.8/4, 63% positive cores) or benign prostate tissue (score = 1.5/4, 25% positive cores) with a mean difference of 0.54 and 1.84, respectively (P < 0.00001 for both). Paradoxically, for localized disease, higher MTA1 protein expression was associated with lower rates of prostate specific antigen recurrence after radical prostatectomy for localized disease. In summary, this study identified an association of MTA1 expression and prostate cancer progression.




This article has been cited by other articles:


Home page
Cancer Res.Home page
M. M. Pomerantz, C. A. Beckwith, M. M. Regan, S. K. Wyman, G. Petrovics, Y. Chen, D. J. Hawksworth, F. R. Schumacher, L. Mucci, K. L. Penney, et al.
Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression
Cancer Res., July 1, 2009; 69(13): 5568 - 5574.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Zhang, L. C. Stephens, and R. Kumar
Metastasis Tumor Antigen Family Proteins during Breast Cancer Progression and Metastasis in a Reliable Mouse Model for Human Breast Cancer
Clin. Cancer Res., March 1, 2006; 12(5): 1479 - 1486.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
X.-y. Zhang, L. M. DeSalle, J. H. Patel, A. J. Capobianco, D. Yu, A. Thomas-Tikhonenko, and S. B. McMahon
Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein
PNAS, September 27, 2005; 102(39): 13968 - 13973.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary
Molecular pathology of prostate cancer
J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Kumar, A. E. Gururaj, R. K. Vadlamudi, and S. K. Rayala
The Clinical Relevance of Steroid Hormone Receptor Corepressors
Clin. Cancer Res., April 15, 2005; 11(8): 2822 - 2831.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.